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Switching antipsychotics: Results of 16-month  
non-interventional, prospective, observational clinical research 
of inpatients with schizophrenia spectrum disorders
The study aims to identify prescribing and switching 
patterns of antipsychotics in clinical practice. A 16-month, 
prospective study was conducted at the Psychiatric Hospi-
tal Idrija, Slovenia. Inpatients (N = 311) with schizophrenia 
spectrum disorders were observed. The causes for switch-
ing antipsychotics and switching strategies were ana-
lyzed. Analyzing a total of 3954 prescriptions, the collect-
ed data confirmed that treatment strategies in this 
psychiatric hospital are very complex. It was found that 37 
percent of inpatients had at least one switch. Moreover, 
switches that included three or more antipsychotics were 
detected. The most common causes for switching antipsy-
chotics were adverse reactions and inefficacy or lack of ef-
ficacy. Among switching options, abrupt switch was re-
corded several times. As some patients are receiving 
several antipsychotics at the same time, it is possible that 
unusual switching occurs in clinical practice. It seems that 
the choice of switching strategy is also affected by the 
cause and urgency for switching an antipsychotic.
Keywords: schizophrenia, switching antipsychotics, 
causes, strategies
Schizophrenia, schizotypal and delusional disorder are mental illnesses that affect 
not only the patient, but also the patient’s family, friends and surroundings. Despite the 
fact that antipsychotics allow a better quality of life for patients, many of them never remit 
and may even fail to eliminate the symptoms of the disease (1). Use of antipsychotics car-
ries risks for the patients (2). The consequence is that it becomes necessary to switch anti-
psychotics in order to achieve better treatment outcomes in patients with schizophrenia 
and provide them with greater safety (1, 3).
The benefits of switching must be balanced against the risk of the new antipsychotic, 
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tible with the medications the patient is already receiving, or even worsen his/her 
psychophysical status (3–6). Causes for switching antipsychotics may differ: adverse reac-
tions (7–12), inefficacy or lack of efficacy (despite patient compliance in the treatment and 
in spite of the optimal dose of the selected antipsychotic) (13–15), drug non-compliance 
(due to a large number of medications, complex dosing, and negative experiences in the 
treatment) (16), drug-drug interactions (due to polypharmacotherapy) (17, 18), and some 
other causes, for example, at the request of the patient (19). As we know, several theoretical 
tapering options of antipsychotics are available (5, 16, 19, 20). In contrast, we do not have 
enough empirical data or clinical research on the antipsychotic switching strategy (20, 21). 
Data are sparse and contradictory, so there is no uniform position about which option of 
switching antipsychotics is the best (21). Moreover, most of previous clinical research was 
focused on switching an individual antipsychotic and was sponsored by pharmaceutical 
companies (21–24).
This research is conducted to examine independently the process of switching anti-
psychotics in psychiatric hospital practice. We endeavored to find the causes for switching, 
analyze the effect of various factors on switching, find out the switching strategies, deter-
mine the duration of switching, and compare the research findings with recommendations 
for switching antipsychotics. To our knowledge, this is the first research on this topic in 
Slovenia.
EXPERIMENTAL
Research design and population
Data were collected in a prospective, observational, non-interventional study of inpa-
tients with schizophrenia, schizotypal and delusional disorder, aged 18 to 65 years, who 
were admitted to the Psychiatric Hospital Idrija, Slovenia, from December 1, 2009 to No-
vember 30, 2010. The exclusion criteria were as follows: inpatients with liver and/or kidney 
diseases, pregnant women, and patients younger than 18 or older than 65 years. Inpatients 
were monitored from the beginning to the end of their hospitalization; the last one was 
discharged in March 2011, so the research period was 16 months. No inpatient dropped 
out from the study.
Data collection
All data were recorded in six special forms prepared for the purpose of the research. 
Demographic information included sex, age, diagnosis, body mass and height, smoking 
status, coffee and alcohol consumption, marital status and number and length of hospital-
ization. All medications prescribed in the ward were recorded. We focused on the use of 
antipsychotics, so we monitored their prescribed doses, modes of administration, and infor-
mation about switching: causes, pre-switching and post-switching doses, strategies, how 
many days were necessary to switch and the success of switches. The collection of adverse 
reactions as the cause for switching antipsychotics contains only the type of adverse reac-
tion, which means that no scales or other exams were used to evaluate them. Values of the 
global assessment of functioning (GAF) score and the clinical global impression (CGI) were 
evaluated only when inefficacy or lack of efficacy was the cause for switching.
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To compare daily doses of antipsychotics, chlorpromazine equivalent daily doses 
(CEDD) were used (25). Discovered switching strategies with antipsychotics were com-
pared with eight available switching options: abrupt switch, ascending switch, descending 
switch, cross-titration, plateau switch, ascending plateau switch, descending plateau 
switch and plateau cross-titration.
Data analysis
Statistical analysis was done using the IBM SPSS statistics 20 software package (IBM 
SPSS, Chicago, IL, USA). Frequencies (percentages) were used to describe categorical vari-




A total of 311 inpatients with 446 hospitalizations were included in the research. De-
mographic parameters of the study sample, which was divided into group A (inpatients 
with switching antipsychotics, N = 116, 37 %) and group B (inpatients without switching 
antipsychotics, N = 195, 63 %), are summarized in Table I.
Most of the patients (47 %) were hospitalized due to one of the types of schizophrenia. 
Paranoid schizophrenia was the predominant diagnosis (32 %), followed by acute and 
transient psychotic disorders (30 %). Catatonic schizophrenia and induced delusional dis-
order, which are rare psychotic disorders, have not been diagnosed in our population.
The portion of males in the observed population was higher than that of females (58 
vs. 42 %) but, on average, females were older than males (44 vs. 41 years) (Table I).
During the observational time, 73 percent of patients (N = 227) were hospitalized once 
and 23 percent (N = 72) were hospitalized for the first time. Moreover, due to the frequent 
relapse of schizophrenia, some inpatients (27 %) were hospitalized several times (one of 
them was hospitalized seven times). Most of the inpatients (77 %) had already been hospi-
talized in the past; the average time of hospitalization was 44 days (Table I).
The inpatients were divided into two groups (group A and group B) to see whether 
the differences in patients' characteristics were connected with the switching of antipsy-
chotics. No significant differences were found between the two groups, pointing to the 
probable absence of correlation between patients' characteristics (Table I) and switching 
antipsychotics.
Use of medications
Inpatients were exposed to a large amount of different drugs (Table II). Analyzing a 
total of 2706 prescriptions (drugs prescribed pro re nata were not taken into account), it was 
found that the most often prescribed drug (among all drugs) was biperiden (N = 231), fol-
lowed by diazepam (N = 177), fluphenazine (N = 157) and olanzapine (N = 155). According 
to the Anatomical Therapeutic Chemical (ATC) classification index, antipsychotics were 
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prescribed most frequently, followed by anxiolytics, antiparkinsonians, antidepressants, 
antiepileptics (mood stabilizers) and cardiovascular drugs (Table II). Since inclusion crite-
ria for patients were psychotic disorders coded as F20–F29, with paranoid schizophrenia 
as predominant diagnosis, it was anticipated that antipsychotics would be the most fre-
quently used drugs. The second most frequently given group of drugs were anxiolytics 
(benzodiazepines), which are used for the treatment of anxiety and its related psycho-
logical and physical symptoms such as emotional, neurotic and sleep disorders. Although 
these drugs were prescribed pro re nata, the majority of patients used them regularly for 
more than two weeks, which constitutes a considerable risk of tolerance and dependence, 
accompanied with withdrawal and rebound syndromes (12). The patients were also given 
cardiovascular drugs for cardiovascular problems, and antidiabetic drugs due to the met-
abolic syndrome (9, 11, 12). Use of these drugs is probably justified since they reduce or 
eliminate adverse reactions of antipsychotics (2).
Use of antipsychotics
We analyzed the prescribed doses of antipsychotics per hospitalization and deter-
mined the average prescribed daily dose and the average number of days of taking a 
particular antipsychotic. To compare our results on prescribing antipsychotics with the 
Table I. Demographic and clinical parameters
Group Aa
No. of patients (%)
Group Bb
No. of patients (%)
Total
No. of patients (%)
Number of patients 116 (37) 195 (63) 311 (100)
Number of 
hospitalizations 129 (29) 317 (71) 446 (100)
Average time of 
hospitalization (days) 66 (min = 2, max = 286) 35 (min = 1, max = 204) 44 (min = 1, max = 286)




(min = 15.8, max = 59.6)
26.8 
(min = 15.6, max = 46.6)
27.4 
(min = 15.6, max = 59.6)
Smokers 77 (66) 136 (70) 213 (69)
Coffee consumers 108 (93) 186 (95) 294 (95)
Alcohol consumers 60 (52) 105 (54) 165 (53)
Married 27 (23) 43 (22) 70 (23)
Not married 89 (77) 152 (78) 241 (78)
m/f 60/56 (52/48) 119/76 (61/40) 179/132 (58/42)
F20.0 43 (37) 55 (28) 98 (32)
BMI – body mass index, m/f – male/female, F20.0 – paranoid schizophrenia
a With switching antipsychotics.
b Without switching antipsychotics.
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prescribing habits, Table III presents the average maintenance dose per day for a drug used 
for its main indication in adults (DDD) according to the ATC classification system and the 
prescribed daily dose per hospitalization (PDD). It was found that amisulpride, clozapine, 
levomepromazine, promazine, quetiapine, risperidone, sulpiride and zuclopenthixol were 
prescribed in too low doses (PDD < DDD) (Table III). Flupenthixol, fluphenazine, halo-
peridol, olanzapine and sulpiride were prescribed in too high doses (PDD > DDD) and 
only paliperidone and ziprasidone were prescribed at the same dose (PDD = DDD). The 
differences between DDD and mean PDD are in some cases substantial. Moreover, the 
differences between max PDD and min PDD are very large for the majority of antipsychot-
ics. Some of them (aripiprazole, olanzapine, paliperidone, quetiapine and ziprasidone) 
were used in maximal recommended doses. These observations imply that dosing of an-
tipsychotics was not optimal. The same conclusion has been drawn recently in an Italian 
district using the same methodological approach (27).
The most frequently prescribed antipsychotic was olanzapine (N = 126, 41 %). This 
result was expected, since the guidelines for the treatment of schizophrenia recommend 
second generation antipsychotics (SGA), the use of which is less risky for patients (30). 
Nevertheless, 35 percent (N = 108) of patients received haloperidol and 35 percent (N = 107) 
of patients received fluphenazine, both of which are first generation antipsychotics (FGA). 
Table II. Summary of prescribing medicationsa





Antiepileptics (mood stabilizers) 185 6.8
Cardiovascular drugs 149 5.5
Anti-infectives 62 2.3
Hypolipidemic agents 49 1.8
Antiulcer drugs 48 1.8
Analgesics 46 1.7
Respiratory system drugs 46 1.7





ATC – Anatomical Therapeutic Chemical classification index
a Drugs that were prescribed pro re nata are not taken into account.
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Although it is known that FGA cause considerable adverse events, such as extrapyramidal 
symptoms, compared to SGA (12), this study revealed that an antipsychotic from the FGA 
group was prescribed to 41 percent of patients. The reasons for such a high percentage of 
prescribed FGA lie in the fact that they represent a traditional and low-priced alternative 
to SGA, they are available in different dosage forms and, finally, they exhibit effective se-
dation in restless and often aggressive patients.
A minority of studied patients (27 %) were treated with one antipsychotic. Two or 
three antipsychotics were concomitantly prescribed in 47 and 22 percent of prescriptions, 
respectively. It was also observed that in 3 percent of prescriptions more than three anti-
psychotics were prescribed concomitantly. Out of 137 prescriptions, four antipsychotics in 
128, five in 8 and six antipsychotics in 1 prescription were prescribed. This is not in agree-
ment with the recommendations of the British Association for Psychopharmacology, 
where it is clearly stated that combinations of antipsychotics should be avoided except in 
Table III. The prescribed daily dose of antipsychotic per hospitalization (PDD) and comparison of the average 












Amisulpride 20 23 (4/210) 400 388 (244) 324 (800/100)
Aripiprazole 48 35 (2/204) 15   16 (6)   15 (30/5)
Clozapine 115 44 (3/279) 300 203 (119) 192 (600/15)
Flupenthixol 8 39 (6/130) 6     9 (4)     8 (18/3)
Fluphenazine 148 35 (2/162) 10   16 (8)   15 (39/3)
Haloperidol 122 31 (1/187) 8   19 (8)   17 (43/2)
Levomepromazine 3 21 (7/38) 300 142 (142) 100 (300/25)
Lithium 8 39 (6/97) – 903 (120) 900 (1164/750)
Lithium R 13 37 (3/79) – 907 (108) 900 (1286/900)
Olanzapine 149 35 (1/162) 10   15 (4)   15 (24/5)
Paliperidone 26 25 (1/82) 6     7 (2)     7 (12/3)
Promazine 29 38 (2/204) 300 175 (122) 150 (419/25)
Quetiapine 66 23 (2/133) 400 286 (223) 217 (800/25)
Quetiapine SR 66 30 (2/106) 400 352 (206) 318 (800/50)
Risperidone 109 30 (2/186) 5     4 (2)     4 (7/1)
Sulpiride 5 15 (3/33) 800 182 (121) 100 (371/100)
Ziprasidone 9 44 (8/94) 80 132 (31) 136 (160/71)
Zuclopenthixol 7 35 (9/72) 30   26 (12)   20 (51/13)
DDD – maintenance dose per day for a drug used for its main indication in adults, PDD – daily dose of antipsychotic per 
hospitalization, R – controlled release , SD – standard deviation, SR – slow (extended) release.
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the case of switching (28). Guidelines of the World Federation of Societies of Biological 
Psychiatry recommend the use of only one antipsychotic (29).
Switching antipsychotics
At least one switch was recorded in 37 percent (N = 116) of patients. During the obser-
vational period, 186 switches were recorded, including 22 percent (N = 68) of patients who 
had one switch, 11 percent (N = 34) two switches, 4 percent (N = 11) three switches, 1 per-
cent (N = 2) five switches and one patient seven switches of antipsychotics.
Average time of switching was 9 days, maximum time was 74 days (quetiapine), and 
minimum time was one day (most antipsychotics).
The prescribed daily doses (PDD) of pre-switching and post-switching antipsychotics 
for the most common switches are given in Table IV. Risperidone was the most frequent 
pre-switching antipsychotic (19 % of all switches) and olanzapine was the most frequent 
post-switching antipsychotic (14 % of all switches).  The most frequent switches were those 
of risperidone to paliperidone (13 cases). Despite the fact that these two drugs have a 
similar pharmacological profile, paliperidone improves patient medication adherence due 
to simple, once daily administration (22).
Antipsychotics vary greatly in potency, which is usually expressed as differences in 
chlorpromazine (or neuroleptic) equivalents. In an attempt to find out if there is a connec-
tion between the daily doses of pre-switching and post-switching antipsychotics, incom-
plete agreement about chlorpromazine equivalents was found. This is mainly due to dif-
ferent methods of assessing antipsychotic chlorpromazine equivalence (manufacturers’ 
Table IV. Prescribed daily doses (PDD) of pre-switching and post-switching antipsychotics 

























Risperidone 2 6 4  Paliperidone 3 12 8
Haloperidol 11 38 27  Fluphenazine 8 30 23
Fluphenazine 10 30 24  Haloperidol 15 38 29
Risperidone 1 6 5  Fluphenazine 5 30 22
Risperidone 1 6 4  Olanzapine 10 20 16
Olanzapine 10 20 15  Risperidone 2 6 4
Haloperidol 30 45 33  Olanzapine 15 20 18
Olanzapine 15 25 20  Clozapine 100 500 210
Risperidone 1 6 3  Aripiprazole 10 30 20
Haloperidol 15 30 27  Risperidone 4 6 6
Quetiapine 75 400 282  Clozapine 100 450 255
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information, clinical studies, and non-clinical/dopamine binding studies), resulting in up 
to a five-fold difference in equivalents (6, 25). As we expected, pre-switching and post-
switching antipsychotic chlorpromazine equivalent daily doses (CEDD) showed that pre-
CEDD and post-CEDD are not usually equal (Fig. 1). In 20 unusual switches, pre-CEDD 
and post-CEDD were not calculated. Fig. 1 shows a comparison between pre-CEDD and 
post-CEDD values.
In 64 percent (N = 119) of cases, the post-switching antipsychotic was a second gen-
eration antipsychotic (SGA): in 72 percent (N = 86) of cases, the pre-switching antipsy-
chotic was SGA, and in 28 percent (N = 33) of cases, the pre-switching antipsychotic was a 
first generation antipsychotic (FGA). In 24 percent (N = 47) of cases, the post-switching 
antipsychotic was FGA: in 55 percent (N = 26) of cases, the pre-switching antipsychotic was 
SGA and in 45 percent (N = 21) of cases, the pre-switching antipsychotic was FGA. In 12 
percent (N = 20) of cases, the post-switching antipsychotics were not defined (depot anti-
psychotics and unusual switches).
Different causes for switching antipsychotics (N = 264) were found (Table V). Adverse 
reactions of antipsychotics as the cause for switching were found in 37 percent of cases. 
Among them, the majority were extrapyramidal symptoms (16 %), mostly caused by halo-
peridol, risperidone or fluphenazine. These results were expected. Adverse reactions that 
followed were sedation (4 %), mostly caused by olanzapine or risperidone, and weight gain 
(4 %) mostly caused by olanzapine. In 24 percent of cases, inefficacy or lack of efficacy was 
the reason for switching: olanzapine (5 %), quetiapine (4 %) and haloperidol (3 %). In 17 
percent of cases, drug non-compliance (inpatient refused medicine) was the cause for 
switching, and in as many as 12 percent of cases, the switch was carried out at the patient’s 
request.
Drug-to-drug interactions can lead to serious adverse reactions, failure of therapy, in-
creased morbidity and mortality, hospital admission, prolonged length of hospital stay and 
elevated costs of treatment (30, 31). Unexpectedly, such interactions as the cause for switch-
ing antipsychotics were not recorded during the study period (17, 18, 25). Antipsychotics 
are very often given together advantageously and uneventfully, but occasionally serious 
Fig. 1. Comparison of pre-switching and post-switching antipsychotic chlorpromazine equivalent 
daily doses (CEDD).
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and even life-threatening interactions occur. These include heat-stroke under hot and hu-
mid conditions, severe constipation or adynamic ileus (18). The most common combinations 
of antipsychotics (analysis of a total of 2706 prescriptions) were clozapine/fluphenazine 
(16 %, N = 441), haloperidol/olanzapine (13 %, N = 338), haloperidol/clozapine (9 %, N = 227), 
olanzapine/fluphenazine (7 %, N = 201) and quetiapine/fluphenazine (7 %, N = 197).
Most switches (92 %, N = 172) included one drug replaced by another, but some un-
usual switches were also detected where at least three antipsychotics were involved in the 
switch (8 %, N = 14). These happened when two post-switching antipsychotics replaced one 
pre-switching (one by two), one post-switching antipsychotic replaced two pre-switching 
(two by one), one post-switching antipsychotic replaced three pre-switching (three by one) 
and two post-switching antipsychotics replaced two pre-switching (two by two). The re-
ported recommendations do not mention such switches (21).
Abrupt switch was recorded in 31 percent, followed by ascending switch (23 %), cross-
titration switch (17 %), a switch with at least three antipsychotics (16 %), descending switch 
(4 %), plateau cross-titration switch (4 %), ascending plateau switch (2 %), plateau switch 
(1 %), and descending plateau switch (1 %). An abrupt switch (therapeutic dose initiation 
of a post-switching antipsychotic and abrupt discontinuation of a pre-switching antipsy-
chotic) was recorded several times, which was not expected because this tapering option 
is recommended only when amisulpride or aripiprazole are switched to paliperidone (12). 
An abrupt switch was most commonly used when adverse reactions of antipsychotics (11 
%) or drug non-compliance (6 %) were the causes for switching. Thus it can be concluded 
that the choice of switching strategy is also affected by the cause and urgency for switch-
ing the antipsychotic. An ascending switch (gradual dose escalation of a post-switching 
antipsychotic and abrupt discontinuation of a pre-switching antipsychotic) was usually 
chosen when inefficacy or lack of efficacy of antipsychotics were observed (9 %) (Table V). 
A larger number of causes (N = 243) than the number of switches (N = 186) observed 
showed that for some switches more than one cause was identified. The relation between 
the switching strategy and the reason for switching was analyzed and the results are 
given in Table V.
Optimal responses to a switch were those when the patient was hospitalized for at 
least two weeks after switching and had no serious adverse reactions or relapse, and some 
positive changes (better functioning) occurred during that period. Sub-optimal responses 
to a switch were those when the patient was hospitalized for at least two weeks after 
switching and had some serious adverse reactions or relapse after switching, and when 
there was no benefit of switching (the level of functioning did not change). Most switches 
were found successful (60 %), but 9 percent of switches could not be evaluated because the 
patients were sent home less than two weeks after switching.
GAF and CGI
The global assessment of functioning (GAF) score was used to measure the inpatients’ 
overall level of functioning and their ability to carry out daily activities. The clinical glob-
al impression (CGI) was used to assess the severity of the inpatient’s mental illness within 
a specified period. Values of CGI and GAF were evaluated only when inefficacy or lack of 
efficacy was the cause for switching. The average value of CGI before switching was 6.1 
(min = 5, max = 7), which means that inpatients were severely ill. The average value of CGI 
after switching was 3.5 (min = 2, max = 5), which means that some inpatients were still 
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Table V. Correlation between switching strategies and causes for switching
















































































Unknown side effects 1 1
Diabetes mellitus 1
Urinary incontinence 1 1
Nausea 1 1
Painful leg 1 1
Insomnia 1
Anxiety 1
Sedation 4 4 1 2
EPS 10 9 2 6 2 1 3 5
Anticholinergic side effects 2 3 1 2
Hypotension, dizziness, fatigue 4 1
Hematologic side effects 1
Weight gain 2 3 4 1 1
Sexual dysfunction 1
Elevations in prolactin 3 2
Inefficacy or lack of efficacy 16 21 2 9 1 1 4 5
Drug noncompliance 15 9 2 6 1 1 6
Drug–drug interactions
At the request of the patient 9 6 2 5 1 1 1 3
Appropriate drug formulation 4 2
Simpler dosing 1 1 1 1
Experience of the psychiatrist 2 1
Deliberate, from FGA to SGA 2 1
Other 4 2 1 2
EPS – extrapyramidal symptoms, FGA – first generation antipsychotic(s), SGA – second generation antipsychotic(s)
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mildly to moderately ill. The average difference between pre-CGI and post-CGI was 2.1 
(min = 0, max = 5). The average value of GAF before switching was 25.6 (min = 5, max = 53), 
which means that inpatients were incapable of functioning in almost all areas. The average 
value of 45.2 (min = 21, max = 91) after switching indicated that some inpatients still had 
serious symptoms of the disease. The average difference between pre-GAF and post-GAF 
was 23.1 (min = 0, max = 67).
In 68 percent of switches due to inefficacy or lack of efficacy of antipsychotics, the 
patients’ functioning and their clinical status were improved (Fig. 2). In 12 percent of 
switches, there were minimal changes. In 10 percent of switches, there were no changes in 
CGI and GAF values, whereas CGI and GAF data were missing in 10 percent of switches. 
This was due to either an interruption of treatment with an antipsychotic due to adverse 
reactions (3 cases), or the patient’s discharge from the hospital in less than two weeks after 
switching (1 case), or drug non-compliance (2 cases).
Major limitations of our study are the lack of information about adverse reactions (no 
information on exams is available), the values of CGI and GAF (evaluated only when inef-
ficacy or lack of efficacy was the cause for switching) and actual drug-drug interactions. In 
addition, some data were not obtained during the study period as we did not interfere with 
the psychiatrists’ decisions (the study was prospective).
CONCLUSIONS
The research was conducted to examine independently the process of switching anti-
psychotics in psychiatric hospital practice in Slovenia. Moreover, for the first time, we 
provide a detailed overview of all drugs used for inpatients with schizophrenia spectrum 
disorders.
Based on the results, we can conclude that the use of antipsychotics in the Psychiatric 
Hospital Idrija is not optimal for at least five reasons. First, the majority of inpatients re-
ceived two or more antipsychotics (73 % of prescriptions) because of too low doses of an 
individual antipsychotic (44 % of antipsychotics were prescribed in doses lower than 
DDD). Second, we detected some unusual switching of antipsychotics (8 %) where at least 
Fig. 2. Effectiveness of switching when the cause for switching was inefficacy or lack of efficacy.
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three antipsychotics were included in the switch. Third, an abrupt switch was recorded 
several times, which was not expected because this tapering option is rarely recommend-
ed. It seems that the choice of switching strategy is also affected by the cause and urgency 
for switching the antipsychotic. Fourth, there is a strong potential for clinically relevant 
drug-drug interactions because of polypharmacotherapy, including antipsychotics, but 
during the study period we did not record any interactions as the cause for switching 
antipsychotics. Finally, some important data was not available during the study period 
due to incomplete medical documentation (CGI and GAF values before and after each 
switch, causes for switching, exams).
The presented results indicate the need for further research to eliminate some limita-
tions of our study and to better understand some deviations in the use of antipsychotics. 
To conclude, once the decision is made to switch an antipsychotic, it is necessary to take an 
individualized switching strategy into account. We therefore suggest that clinical pharma-
cists should be involved in the treatment of psychiatric patients using polypharmaco-
therapy.
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